Celularity (Celularity) Institutional Ownership : 3.61% (As of May. 24, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Celularity Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Celularity's institutional ownership is 3.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Celularity's Insider Ownership is 38.02%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Celularity's Float Percentage Of Total Shares Outstanding is 53.12%.

Celularity Institutional Ownership Historical Data

The historical data trend for Celularity's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celularity Institutional Ownership Chart

Celularity Historical Data

The historical data trend for Celularity can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	2.96	4.15	2.92	2.09	2.09	2.07	1.86	0.44	3.15	3.61

Celularity Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Celularity (Celularity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

170 Park Avenue, Florham Park, NJ, USA, 07932

Website

https://www.celularity.com

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Executives

Kok Thay Lim	director	22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri	director, officer: Chief Executive Officer	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d.	director	C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting	10 percent owner	24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne	officer: See Remarks	533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher	officer: General Counsel	CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler	director	C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith	director	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur	director	31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover	director, officer: Chief Technology Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido	officer: Pres, Functional Regeneration	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones	director, officer: Chief Business Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932